A5102882777- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Extracellular vesicles in disease
- Nanoplatforms for cancer theranostics
- Ferroptosis and cancer prognosis
- Nanoparticle-Based Drug Delivery
- Diagnosis and Treatment of Venous Diseases
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Supramolecular Self-Assembly in Materials
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Wound Healing and Treatments
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Dendrimers and Hyperbranched Polymers
- Transgenic Plants and Applications
- Advanced Drug Delivery Systems
Sun Yat-sen University
2019-2025
The lysosome-targeting chimera (LYTAC) strategy provided a very powerful tool for the degradation of membrane proteins. However, synthesis LYTACs, antibody-small molecule conjugates, is challenging. ability antibody-based LYTACs to penetrate solid tumor limited as well, especially cross blood-brain barrier (BBB). Here, we propose covalent chimeric peptide-based targeted platform (Pep-TACs) by introducing long flexible aryl sulfonyl fluoride group, which allows proximity-enabled cross-linking...
Excessive and persistent inflammation after injury lead to chronic wounds, increased tissue damage or even aggressive carcinogenic transformation. Effective wound repair could be achieved by inhibiting overactive immune cells the injured site. In this study, we obtained high concentration of PD-L1 in exosomes from either genetically engineered overexpressing IFN-γ stimulated cells. We found that exosomal is specially bound PD-1 on T cell surface, suppressed activation. Interestingly,...
Ferroptosis, iron-dependent cell death, is an established mechanism for cancer suppression, particularly in hepatocellular carcinoma (HCC). Sorafenib (SOR), a frontline drug the treatment of HCC, induces ferroptosis by inhibiting Solute Carrier family 7 member 11 (SLC7A11), with inadequate notably contributing to SOR resistance tumor cells. To further verify biological targets associated analysis Cancer Genome Atlas (TCGA) database was performed find significant co-upregulation SLC7A11 and...
T cell activation by immune allorecognition is a major contributing factor toward the triggering of organ rejection. Immunosuppressive drugs have to be taken after transplantation, but long-term use these increases risks infection and other serious disorders. Here, we showed dysregulation programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) cytotoxic T-lymphocyte-associated protein 4/cluster differentiation 80 (CTLA-4/CD80) in spleen two transplantation models. Using bioengineering...
In clinical practice, thymopentin (TP‐5) is a commonly utilized immunomodulatory peptide drug. The relatively short half‐life of TP‐5, however, significantly limits its applicability in immunotherapy. Inspired by the structure TLR2 ligand lipopeptide Pam3CSK4, fatty acid‐modified TP‐5 peptides were designed and synthesized this study. Utilizing amphiphilicity, they sonicated to assemble into nanoparticles with diameters approximately 100 nm. Compared monopalmitate‐modified nanoparticle has...
Oral cancer vaccines are convenient and safe, with the presence of gut-associated lymphoid tissue (GALT) involved intestinal Peyer's patch (PPs) containing microfold (M) cells housing abundant underneath dendritic (DCs). Here, we found that endocytic receptors glycoprotein 2 (GP2) dectin-1 respectively expressed on M DCs high specificity. Then, discovered a gastrointestinal hydrolysis-resistant D-peptide DGPBP-2(1-8) targeting GP2 by phage display screening optimization. was conjugated to...
PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved FDA, successfully representing the combination therapy of immunotherapy and first time in 2020. However, PD-L1 Tecentriq albumin paclitaxel using similar strategy failed to achieve expected effect. Therefore, it is still necessary explore new effective chemotherapy-based strategies. We developed a cell membrane-derived programmed death-ligand 1(PD-1) nanovesicle encapsulate low-dose...